205 related articles for article (PubMed ID: 24280866)
1. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia.
Scherr M; Elder A; Battmer K; Barzan D; Bomken S; Ricke-Hoch M; Schröder A; Venturini L; Blair HJ; Vormoor J; Ottmann O; Ganser A; Pich A; Hilfiker-Kleiner D; Heidenreich O; Eder M
Leukemia; 2014 Mar; 28(3):554-65. PubMed ID: 24280866
[TBL] [Abstract][Full Text] [Related]
2. Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax.
Li D; Yuan Y; Meng C; Lin Z; Zhao M; Shi L; Li M; Ye D; Cai Y; He X; Ye H; Zhou S; Zhou H; Gao S
Clin Epigenetics; 2024 Mar; 16(1):48. PubMed ID: 38528641
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL
Budhraja A; Turnis ME; Churchman ML; Kothari A; Yang X; Xu H; Kaminska E; Panetta JC; Finkelstein D; Mullighan CG; Opferman JT
Clin Cancer Res; 2017 Dec; 23(24):7558-7568. PubMed ID: 28974549
[No Abstract] [Full Text] [Related]
4. miR-451a induced apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells by targeting IL-6R.
Jiang T; Chen J; Huang XB; Li YX; Zhong L
Neoplasma; 2018 Nov; 65(6):907-914. PubMed ID: 30334451
[TBL] [Abstract][Full Text] [Related]
5. Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.
Vázquez-Franco JE; Reyes-Maldonado E; Vela-Ojeda J; Domínguez-López ML; Lezama RA
Leuk Res; 2012 Jul; 36(7):862-7. PubMed ID: 22591684
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
[TBL] [Abstract][Full Text] [Related]
7. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
8. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.
Koss B; Morrison J; Perciavalle RM; Singh H; Rehg JE; Williams RT; Opferman JT
Blood; 2013 Aug; 122(9):1587-98. PubMed ID: 23881917
[TBL] [Abstract][Full Text] [Related]
9. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 Jan; 356(2 Pt B):597-605. PubMed ID: 25305453
[TBL] [Abstract][Full Text] [Related]
10. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia.
Xishan Z; Ziying L; Jing D; Gang L
Sci Rep; 2015 Jul; 5():12460. PubMed ID: 26228085
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
13. The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.
Xishan Z; Xianjun L; Ziying L; Guangxin C; Gang L
Cancer Gene Ther; 2014 Sep; 21(9):397-404. PubMed ID: 25213664
[TBL] [Abstract][Full Text] [Related]
14. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA.
Guo G; Kang Q; Zhu X; Chen Q; Wang X; Chen Y; Ouyang J; Zhang L; Tan H; Chen R; Huang S; Chen JL
Oncogene; 2015 Apr; 34(14):1768-79. PubMed ID: 24837367
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and treatment of Ph+ leukemia: recent insights from mouse models.
Van Etten RA
Curr Opin Hematol; 2001 Jul; 8(4):224-30. PubMed ID: 11561160
[TBL] [Abstract][Full Text] [Related]
16. Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Suh SP; Kee SJ; Lim WH; Song JW; Lee SK; Kim JP; Shin JH; Ryang DW
Clin Chem Lab Med; 2000 Sep; 38(9):939-44. PubMed ID: 11097354
[TBL] [Abstract][Full Text] [Related]
17. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
18. Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Doki N; Kitaura J; Uchida T; Inoue D; Kagiyama Y; Togami K; Isobe M; Ito S; Maehara A; Izawa K; Kato N; Oki T; Harada Y; Nakahara F; Harada H; Kitamura T
Int J Hematol; 2012 Feb; 95(2):167-75. PubMed ID: 22189847
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the miRNA expression by TEL/AML1, BCR/ABL, MLL/AF4 and TCF3/PBX1 oncoproteins in acute lymphoblastic leukemia (Review).
Organista-Nava J; Gómez-Gómez Y; Illades-Aguiar B; Leyva-Vázquez MA
Oncol Rep; 2016 Sep; 36(3):1226-32. PubMed ID: 27431573
[TBL] [Abstract][Full Text] [Related]
20. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
